Results

1–10 of 14 results for Complement

Preservation of Vision by ANX007: Clinical Results and Anatomic Changes From the Phase 2 ARCHER Trial
Joel Pearlman, MD, PhD
Annual Meeting Talks
2024
First Time Results of VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy
Omer Trivizki, MD, MBA
Updates from the Field
2025
Inhibition of C1q Protects Photoreceptor Synapses in a Light Damage Model and Is a Potential Treatment for Geographic Atrophy
Patrick Dewey Williams, MD
Annual Meeting Talks
2022
Association Between Dysfunctional Complement Factor I: Rare Variant Status and Progression to Advanced AMD Outcomes
Johanna M. Seddon, MD, ScM, FARVO, FASRS
Annual Meeting Talks
2022
Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy
Glenn J. Jaffe, MD
Annual Meeting Talks
2022
Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Utilizing Novel Sialic Acid-Coated Nanoparticles
Robert L. Avery, MD
Updates from the Field
2024
Beyond Complement: A Novel FAS Inhibition Approach for Neuroprotection in GA
Vaidehi S. Dedania, MD
Updates from the Field
2024
Evaluating ANX007, a Novel C1q Inhibitor, in the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration: The ARCHER Study
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, and GATHER1 Study: Results From a Post-Hoc Analysis of Nascent Geographic Atrophy
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2021